The increase in CD8+ GrzB+ T cells, CD8+ IFNγ+ T cells and CD4+ IFNγ+ T cells under combination therapy indicated activation of T cell-mediated tumor toxicity (Fig. 5C–H and Figure S5E). This evidence concerns the gene CD8A and neoplasm.